Fundraising FoxDigitalis Ventures — 2024 Investments
8 investments dated 2024 · listed companies and verified rows first · show all
Judo Bio develops oligonucleotide medicines, including ligand-siRNA conjugate drugs, delivered to the kidney for systemic and renal diseases using its STRIKE (Selectively Targeting RNA Into KidnEy) platform.
BiotechHealthtechCambridge, US
Andrew Fraley(Co-founder)inAlfica SehgalinOMMER CHOHAN(Executive Officer)inJAMES JEFFREY GOATER(Executive Officer, Director)Simon Read(CEO)inWilliam Ho
Co-investorsAtlas VentureDroia VenturesThe Column GroupYK Bioventures
Alpha-9 Oncology develops radiopharmaceuticals for cancer treatment, with a portfolio of molecules in clinical and preclinical development.
BiotechDigital HealthMedical DevicesVancouver, CA
François Bénard(Founder)Kuo-Shyan Lin(Founder)David Perrin(Founder)
Co-investorsAndreessen HorowitzAscenta CapitalDelos CapitalFrazier Life SciencesGeneral CatalystLightspeed Venture Partners+9 more
.png)
Ascend is a gene-to-GMP development partner that helps life-science companies advance advanced therapy products from the research bench through clinical stages.
BiotechHealthtechMedical DevicesMunich, DE
Evis Hursever(Executive Officer)Wesley McConnell(Executive Officer)inMichael Stella(Executive Officer, Director)William Hawkins(Executive Officer)
BoardMichael Beecham(Director)Andrew Kozlov(Director)
Co-investorsCathay HealthDCVC (Data Collective)Monograph Capital Partners4BIO Capital
Cardurion is a cardiovascular disease-focused company developing therapeutics, with a pipeline advanced through clinical development, trial design, regulatory affairs, and commercialization.
BiotechDigital HealthHealthtechMedical DevicesBurlington, US
Michael E. Mendelsohn(Founder and Chief Strategy Officer)in
Co-investorsBain CapitalAscenta CapitalDelos CapitalNew Enterprise Associates (NEA)Bain Capital Life SciencesBain Capital Tech Opportunities+4 more
Elegant Bio develops DNA synthesis technology and services, offering ENFINIA™ DNA synthesis at scale for biotech and research applications.
BiotechDeep TechSan Carlos, US
Matthew Hill(Executive Officer, Director)in
BoardPeter Zhou(Director)inCain McClary(Director)inJonathan Sheena(Director)in
Co-investorsACVC PartnersAndreessen HorowitzIn-Q-TelRaptor GroupTriatomic CapitalAME Cloud Ventures+1 more
Expressable provides speech therapy services using research-based techniques with a focus on family engagement and accessibility.
Digital HealthHealthtechSaaSAustin, US
Nicholas Barbara(Executive Officer, Director)inLeanne Sherred(President and Chief Clinical Officer)inBenjamin Pincus(Executive Officer)inSpencer Magloff(Executive Officer)inRyan Hinojosa(Executive Officer)
Co-investorsF-Prime CapitalLerer HippeauNextView VenturesHarbourVest Partners (Canada)
Genomics company building a multi-ancestry biobank and AI-driven analytics for clinical genetic testing and drug discovery.
HealthtechMiami Lakes, US
Carlos D. Bustamante(Executive Officer, Director)inArthur Polk(Executive Officer)Alexander Ioannidis(Director)
BoardWale Ayeni(Director)inMohit Kaushal(Director)Nicholas Katsanis(Director)
Co-investorsCEI VenturesCitta CapitalF-Prime CapitalFounder CollectiveFunction VenturesHelios Digital Ventures+4 more
Nuvig Therapeutics is a biotech company developing immune-modulating therapies for autoimmune and chronic inflammatory diseases, using an endogenous regulatory mechanism intended to treat inflammation without compromising broader immune function.
BiotechLongevity
Co-investorsSanofi Venturesabrdn plcAlexandriaB CapitalGlobal BioAccess FundLeaps by Bayer+4 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.